FindTrial
Sign In

Genomic Study of Lung Cancer

Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing in Lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/01/017085
Enrollment
200
Registered
2019-01-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung

Interventions

None listed

Sponsors

TMAI PAI ENDOWMENT CHAIR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed cases of lung cancer. 2. Age 18 years of age. 3. Patients who are willing to give informed consent. 4. Patients who have not received Chemotherapy or Radiotherapy for treatment before.

Exclusion criteria

Exclusion criteria: 1. Age more than 70 and less than 18 years of age. 2. Patients not willing to give informed consent. 3. Patients who have received Chemotherapy or Radiotherapy for treatment before.

Design outcomes

Primary

MeasureTime frame
Genetic mutations in circulating tumor DNA of lung cancer patients.Timepoint: Genetic mutations in circulating tumor DNA of lung cancer patients will be assessed within 6 months of the blood collection.—

Secondary

MeasureTime frame
Clinical response to treatmentTimepoint: 1 year—

Countries

India

Contacts

Public ContactSONAL SEKHAR

MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES

sonal.sekhar@manipal.edu7411338846

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026